The table as follows shows the adverse reactions reported during the 182-day double-blind period of a Phase III clinical trial of ANDROGEL 16.2 mg/g gel and more frequently in the ANDROGEL 16.2 mg/g gel treated group (n=234) than in the placebo treated group (n=40). (See Table 1.)

Due to the presence of alcohol in this medicine, frequent application to the skin may cause skin irritation and dryness.
The following adverse reactions have been identified during the post-approval period of ANDROGEL 16.2 mg/g. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a clear causal relationship with drug exposure. (See Table 2.)

The following adverse reactions were identified during the post-approval period for products containing testosterone. (See Table 3.)

ADR Reporting Statement: Important: Immediately seek medical attention at the first sign of adverse drug reaction.
View ADR Reporting Link